ELND005, a small molecule drug candidate for Alzheimer's disease, is specifically designed to target the abnormal forms of beta amyloid (“Aβ”), which are believed to play a fundamental role in the development of Alzheimer's disease. In preclinical studies, ELND005 has been shown to stop and/or reverse the progression of Alzheimer's disease pathologies and symptoms by neutralizing Aβ oligomers, preventing the formation of Aβ fibrils, and breaking down existing fibrils - Mechanism of Action movie
Key Properties of ELND005

• Oral formulation
• Readily crosses the blood-brain-barrier
• Reduces Aβ burden, neuroinflammation and vascular amyloid loads
• Inhibits toxic effects of Aβ oligomers on neuron-to-neuron communication

Clinical Development

• Phase II clinical trial in mild-to-moderate Alzheimer's disease completed in 2010 [Link]